Stem Cell Company CardioCell Utilizes BioLife Solutions CryoStor® in Phase II … – MarketWatch
|
Stem Cell Company CardioCell Utilizes BioLife Solutions CryoStor® in Phase II …
MarketWatch In July 2015, Frost & Sullivan forecasted that the stem cell therapy market is expected to be worth $40 billion by 2020 and $180 billion by 2030. The Global Healthcare Cold Chain Logistics Market Report & Forecast published by the IMARC Group forecasts … |
